The average one-year price target for Protalix BioTherapeutics (NYSEAM:PLX) has been revised to $11.22 / share. This is a decrease of 12.00% from the prior estimate of $12.75 dated January 11, 2026.

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Pluxee is on investors’ radar today Pluxee (ENXTPA:PLX) has drawn fresh ...

PLX-200 is an oral compound comprised of gemfibrozil, an FDA-approved lipid regulating agent. According to the company, gemfibrozil’s ability to cross the blood-brain barrier and its established ...

Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. Its pipeline includes PLX-100, a preclinical ...

Polaryx (PLYX) Therapeutics announces it will be presenting a late-breaking abstract on new data for PLX-200, an investigational therapy for the treatment of Krabbe disease at the 22nd Annual ...

) has been revised to $11.22 / share. This is a decrease of 12.00% from the prior estimate of $12.75 dated January 11, 2026. The price target is an average of many targets provided by analysts. The ...

Just over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the end of March, with its R&D projects transferred to other areas of the Japanese group. It's the ...

Learn how to use and get the most from Google Docs, Sheets, Slides, Meet, Keep, Forms, Gmail, and other apps in Google’s Workspace productivity suite. From its humble origins as a collection of cloud ...

Minecraft remains one of the best games of all time over a decade on from its release, but spending such a long time in one game could lead to you running out of ideas. We've been there: you've ...

Explore the NYSE:PLX financials. Find the Protalix financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers from key financial ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...